Clinical Efficacy Observation Of Yangzheng Xiaoji Capsules Combined With Camrelizumab And Apatinib In The Treatment Of Middle And Advanced Hepatocellular Carcinoma

Objective:To observe the effect of Yangzheng Xiaoji capsules on the efficacy and safety of carrilizumab combined with apatinib in the treatment of patients with middle and advanced hepatocellular carcinoma with Qi deficiency and blood stasis type.To provide some research basis for the combination of Chinese and Western medicine in the treatment of middle and advanced hepatocellular carcinoma.Methods:A total of 60 patients with middle and advanced hepatocellular carcinoma who were hospitalized in the Oncology Department of Anhui Hospital of Traditional Chinese Medicine from December 2021 to December 2022 and met the inclusion criteria were randomly divided into observation and control groups,with 30 patients included in each group.In the control group,the patients were were treated with Camrelizumab(200 mg/dose,3 weeks/dose,21 d for 1 course)and oral apatinib250mg/dose once daily.The observation group added Yangzheng Xiaoji capsule orally to the control group,4 capsules each time,3 times a day.The immune function,solid tumor size,TCM syndrome score,clinical laboratory indexes and adverse reactions of the two groups before and after 4 cycles of treatment were recorded and statistically analyzed.Results:1.The CD3+T,CD4+T and CD4+/CD8+ in the observation group and the control group increased after treatment compared with those before treatment,and the differences were statistically different(P<0.05),while the CD8+T was not statistically different from that before treatment(P>0.05).After treatment,the CD3+T and CD4+T in the observation group and the control group were statistically different(P<0.05),and the comparison of CD4+/CD8+ was statistically significantly different(P<0.01).2.The NLR of both the observation and control groups decreased after treatment compared with that before treatment(P<0.05),and the NLR decreased more significantly in the observation group after treatment(P <0.01).There was no statistical difference in PLR between the two groups after treatment compared with that before treatment(P>0.05).3.There was no statistical difference in the evaluation of solid tumor efficacy and tumor marker AFP between the two groups of patients after treatment(P >0.05).4.The differences in KPS scores and TCM symptom scores between the two groups after treatment were statistically significant(P < 0.05).(2)The incidence of weakness was lower in the observation group than in the control group after treatment(P < 0.05),but the overall safety was not statistically different between the two groups(P > 0.05).Conclusion:For patients with middle and advanced hepatocellular carcinoma,the addition of Yangzheng Xiaoji capsule can enhance the immune function of patients and improve the efficacy of immunotherapy to a certain extent by increasing the levels of CD3+T,CD4+T,CD4+/8+and decreasing the level of NLR,compared with the combination of Camrelizumab and apatinib,effectively improving the clinical symptoms and survival quality of patients.